- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04843098
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 1/2 open label, single arm study, and is divided into three phases: the single-agent dose-escalation phase Ia trial, the TL117 plus paclitaxel dose-escalation phase Ib trial, and the open label, multicenter phase 2 trial of TL117 plus paclitaxel.
Adverse events and dose limiting toxicities will be assessed from the first dose of study drug though day 28. When the maximum tolerated dose (MTD) of TL117 plus paclitaxel is determined, additional patients will be treated at the defined RP2D dose until occurrence of unacceptable toxicity, disease progression or withdrawal of consent or death.
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Ye Guo, Dr
- Telefonnummer: 021-38804518
- E-post: pattrickguo@gmail.com
Studer Kontakt Backup
- Navn: Wei Peng, Dr
- Telefonnummer: 021-38804518
- E-post: pengwei8324@163.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18-70 years old for Phase 1a, 18-75 years old for Phase 1b and 2;
- Histologically and/or cytologically confirmation of recurrent/metastatic squamous cell carcinoma of the head and neck;
- At least one evaluable or measurable tumor lesion;
- Adequate performance status;
- A minimum life expectancy of > 3 months;
- Adequate cardiac, kidney, and liver function;
- Willingness of all subjects of childbearing potential to use acceptable methods of birth control;
Exclusion Criteria:
- Any chemotherapy, radiotherapy, targeted therapy, immunotherapy, endocrine therapy and other systematic anti-tumor therapies within 4 weeks prior to the first dose of the study drug (some exceptions apply)
- Prior or current PI3K inhibitor therapy;
- Type 1 or type 2 diabetes requiring antihyperglycemic medication;
- Major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the first dose, or required elective surgery during the study period;
- Any unresolved toxicities from prior therapy greater than Grade 1;
- Inability to swallow, or serious gastrointestinal absorption conditions;
- History of immunodeficiency;
- Active central nervous system metastases;
- Active hepatitis B or C virus infection;
- Uncontrolled active infection;
- Serious cardiovascular disease;
- Clinically uncontrollable effusion in the third space;
- Known allergy and/or contraindications to paclitaxel;
- Known alcohol or drug dependence;
- Mental disorders or poor compliance;
- Pregnant or lactating women;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Single arm, open label
Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
|
TL117 capsules orally once daily
Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatment
Tidsramme: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
|
Per DLT criteria as defined in protocol
|
From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
|
Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatment
Tidsramme: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
|
Per DLT criteria as defined in protocol
|
From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
|
Phase II - Objective response rate (ORR)
Tidsramme: Every 8 weeks from date of first treatment until date of last treatment up to 12 months
|
Objective response rate (ORR): percentage of patients with best overall response of complete response (CR) and partial response (PR) according to RECIST v1.1.
|
Every 8 weeks from date of first treatment until date of last treatment up to 12 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer, kjertel og epitel
- Neoplasmer i hode og nakke
- Neoplasmer, plateepitelceller
- Karsinom
- Karsinom, plateepitel
- Plateepitelkarsinom i hode og nakke
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Paklitaksel
Andre studie-ID-numre
- TL-117-202001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .